{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:16Z","timestamp":1791727756288,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11912-018-0662-5","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T20:32:15Z","timestamp":1517949135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["From a Patient Advocate\u2019s Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?"],"prefix":"10.1007","volume":"20","author":[{"given":"Debra L.","family":"Madden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"662_CR1","unstructured":"A brief history of immunotherapy. Targeted oncology. Published online: Aug 21, 2014. \n                      http:\/\/www.targetedonc.com\/publications\/special-reports\/2014\/immunotherapy-issue3\/a-brief-history-of-immunotherapy\n                      \n                    ."},{"issue":"4","key":"662_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. \n                      https:\/\/doi.org\/10.1016\/j.cell.2017.01.017\n                      \n                    .","journal-title":"Cell"},{"issue":"7378","key":"662_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139. \n                      https:\/\/doi.org\/10.1038\/nature10673\n                      \n                    .","journal-title":"Nature"},{"issue":"2","key":"662_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u20133. \n                      https:\/\/doi.org\/10.1016\/S0022-5347(17)58737-6\n                      \n                    .","journal-title":"J Urol"},{"issue":"2","key":"662_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","volume":"18","author":"RJ Sylvester","year":"2011","unstructured":"Sylvester RJ. Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol. 2011;18(2):113\u201320. \n                      https:\/\/doi.org\/10.1111\/j.1442-2042.2010.02678.x\n                      \n                    .","journal-title":"Int J Urol"},{"issue":"5022","key":"662_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","volume":"1","author":"M Burnet","year":"1957","unstructured":"\u2022\u2022 Burnet M. Cancer\u2014a biological approach. Br Med J. 1957;1(5022):779\u201386. The author, along with the author cited below, was the first to propose the theory of immunosurveillance, suggesting that tumor cell neoantigens could trigger an effective immune response to eliminate a developing cancer. \n                      https:\/\/doi.org\/10.1136\/bmj.1.5022.779\n                      \n                    .","journal-title":"Br Med J"},{"issue":"2","key":"662_CR7","first-page":"137","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber R. The immunobiology of cancer immunosurveillance and immunoediting. CellPress. 2004 Aug;21(2):137\u201348.","journal-title":"CellPress"},{"key":"662_CR8","first-page":"529","volume-title":"Cellular and humoral aspects of the hypersensitive states","year":"1959","unstructured":"\u2022\u2022 Thomas L, Lawrence HS, editors. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959. p. 529\u201332. The author originally proposed the role of immunosurveillance as a primary defense against cancer, theorizing that it was evolutionary in nature and that complex organisms must have immune mechanisms to protect the host against cancer similar to those that resulted in organ transplant rejection."},{"issue":"3\u20134","key":"662_CR9","first-page":"329","volume":"55","author":"L Thomas","year":"1982","unstructured":"\u2022\u2022 Thomas L. On immunosurveillance in human cancer. Yale J Biol Med. 1982;55(3\u20134):329\u201333. This article further discusses immuno-protective mechanisms against cancer similar to those that brought about homograft rejection and the problems that resulted in fierce debate concerning whether the human\u2019s natural immune defenses could be protective against non-viral cancers.","journal-title":"Yale J Biol Med"},{"issue":"6","key":"662_CR10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1073\/pnas.56.6.1699","volume":"56","author":"LJ Old","year":"1966","unstructured":"Old LJ, Boyse EA, Oettgen HF, DeHarven E, Geering G, Williamson B, et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt\u2019s lymphoma cells. Proc Natl Acad Sci U S A. 1966;56(6):1699\u2013704. \n                      https:\/\/doi.org\/10.1073\/pnas.56.6.1699\n                      \n                    .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"662_CR11","unstructured":"The Big IF in Cancer: will the natural drug interferon fulfill its early promise? TIME. March 31, 1980."},{"issue":"1","key":"662_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/108854185779048906","volume":"6","author":"JK Weltman","year":"1985","unstructured":"Weltman JK. The 1984 Nobel laureates in medicine (immunology): J.F. Kohler, C. Milstein, N.K. Jerne. N Engl Reg Allergy Proc. 1985;6(1):84\u20135. \n                      https:\/\/doi.org\/10.2500\/108854185779048906\n                      \n                    .","journal-title":"N Engl Reg Allergy Proc"},{"issue":"11","key":"662_CR13","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z","volume":"21","author":"C Milstein","year":"1999","unstructured":"\u2022\u2022 Milstein C. The hybridoma revolution: an offshoot of basic research. BioEssays. 1999;21(11):966\u201373. This narrative article describes how his interest in antibody diversity enabled him to develop somatic cell genetic techniques, ultimately leading to the develop of monoclonal antibodies in vitro. \n                      https:\/\/doi.org\/10.1002\/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z\n                      \n                    .","journal-title":"BioEssays"},{"key":"662_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-540-73259-4_1","volume":"181","author":"A Nissim","year":"2008","unstructured":"Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Hand Exp Pharmacol. 2008;181:3\u201318. \n                      https:\/\/doi.org\/10.1007\/978-3-540-73259-4_1\n                      \n                    .","journal-title":"Hand Exp Pharmacol"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"357027","DOI":"10.1155\/2014\/357027","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027\u20139. \n                      https:\/\/doi.org\/10.1155\/2014\/357027\n                      \n                    .","journal-title":"Chemother Res Pract"},{"issue":"6","key":"662_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/msj.20220","volume":"77","author":"SJ Baker","year":"2010","unstructured":"Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med. 2010;77(6):573\u201386. \n                      https:\/\/doi.org\/10.1002\/msj.20220\n                      \n                    .","journal-title":"Mt Sinai J Med"},{"issue":"9","key":"662_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrclinonc.2012.127","volume":"9","author":"F Meric-Bernstam","year":"2012","unstructured":"Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012;9(9):542\u20138. \n                      https:\/\/doi.org\/10.1038\/nrclinonc.2012.127\n                      \n                    .","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"662_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73. \n                      https:\/\/doi.org\/10.1186\/s12916-016-0623-5\n                      \n                    .","journal-title":"BMC Med"},{"issue":"1","key":"662_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. \n                      https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012\n                      \n                    .","journal-title":"Immunity"},{"key":"662_CR20","unstructured":"Pickett, JM (2012) Provenge researcher threatened for questioning company studies. ExpertBriefings.com. \n                      http:\/\/www.expertbriefings.com\/news\/provenge-researcher-threatened-for-questioning-company-studies\/\n                      \n                    ."},{"issue":"4","key":"662_CR21","first-page":"197","volume":"36","author":"E Anassi","year":"2011","unstructured":"Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. PT. 2011;36(4):197\u2013202.","journal-title":"PT"},{"key":"662_CR22","unstructured":"Lichtenfeld L (2008) Kidney cancer vaccine: much hype, little hope. Dr. Len\u2019s Blog. \n                      http:\/\/blogs.cancer.org\/drlen\/2008\/07\/03\/kidney-cancer-vaccine-much-hype-little-hope\/\n                      \n                    ."},{"issue":"9633","key":"662_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","volume":"372","author":"C Wood","year":"2008","unstructured":"Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomized phase II trial. Lancet. 2008;372(9633):145\u201354. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(08)60697-2\n                      \n                    .","journal-title":"Lancet"},{"issue":"9633","key":"662_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0140-6736(08)60698-4","volume":"372","author":"JC Yang","year":"2008","unstructured":"\u2022\u2022 Yang JC. Vitespen: a vaccine for renal cancer? Lancet. 2008;372(9633):92\u20133. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(08)60698-4\n                      \n                    . This article is an editorial that accompanied the kidney cancer vaccine study cited directly above. The editorial\u2019s author took issue with the investigators, since although the study results were negative, showing no evidence that the vaccine significantly decreased time to recurrence in patients with renal cell carcinoma, they did an unplanned post-hoc analysis and included those results in their paper, stating that for those patients with \u201cintermediate-risk\u201d renal cell carcinoma, the vaccine decreased recurrence as compared to control patients. The editorial\u2019s author also outlined the study\u2019s technical failings, emphasized that the study results do not support their hypothesis that the vaccine was beneficial for some patients, and criticized the use of unplanned, post-hoc analyses \u201cto salvage underpowered studies or those that fail to reject the null hypothesis.\u201d","journal-title":"Lancet"},{"key":"662_CR25","unstructured":"Dearnent A (2016) Don\u2019t let cancer immunotherapy hope give way to hype. Forbes. \n                      https:\/\/www.forbes.com\/sites\/mergermarket\/2016\/05\/23\/dont-let-cancer-immunotherapy-hope-give-way-to-hype\/#5b1d6dc81183\n                      \n                    ."},{"key":"662_CR26","unstructured":"FDA News Release. FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. Aug. 30, 2017; .\n                      https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm574058.htm\n                      \n                     Accessed September 16, 2017."},{"key":"662_CR27","unstructured":"Hagen T (2017) Novartis sets a price of $475,000 for CAR T-cell therapy. OncoLive. \n                      http:\/\/www.onclive.com\/web-exclusives\/novartis-sets-a-price-of-475000-for-car-tcell-therapy"},{"issue":"1","key":"662_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","volume":"9","author":"W Ma","year":"2016","unstructured":"\u2022\u2022 Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47. This article summarizes current knowledge concerning immune checkpoint inhibitors with anti-PD-1 and anti-CTLA-4 monoclonal antibodies in the treatment of advanced solid tumors, including efficacy and the remaining unmet need to develop biomarkers and assays to identify those patients most likely to benefit from immunotherapy and to help avoid irAEs. \n                      https:\/\/doi.org\/10.1186\/s13045-016-0277-y\n                      \n                    .","journal-title":"J Hematol Oncol"},{"issue":"4","key":"662_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8\n                      \n                    .","journal-title":"Lancet Oncol"},{"key":"662_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"\u2022\u2022 Bellmunt J, Powled T, Vogelzang NJ. A review of the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58\u201367. \n                      https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.007\n                      \n                    . This article reviews the evolution of the treatment of bladder cancer, focusing on the role of immunotherapy, beginning with the bacterial BCG vaccine to modern checkpoint inhibition with CTLA-4 and PD-L1 inhibitors.","journal-title":"Cancer Treat Rev"},{"key":"662_CR31","unstructured":"Immunotherapy in patients with active autoimmune disease. ASCO-SITC Clinical-Immuno-oncology Symposium Daily News. 2017. \n                      https:\/\/immunosym.org\/daily-news\/immunotherapy-patients-active-autoimmune-disease\n                      \n                    ."},{"key":"662_CR32","unstructured":"Green LM. Immunotherapy in cancer care: educating patients about what to expect. Oncology Nursing News website. \n                      http:\/\/nursing.onclive.com\/publications\/oncology-nurse\/2015\/june-2015\/immunotherapy-in-cancer-care-educating-patients-about-what-to-expect#sthash.FeNfHPaO.dpuf\n                      \n                    . Published June 30, 2015"},{"key":"662_CR33","unstructured":"Postow M, Wolchok J (2016) Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate website. \n                      http:\/\/www.uptodate.com\/contents\/toxicities-associated-with-checkpoint-inhibitor-immunotherapy\n                      \n                    . Literature review current through. Updated Jan 6, 2016"},{"key":"662_CR34","unstructured":"Gay N, Prasad V (2017) Few people actually benefit from \u201cbreakthrough\u201d cancer immunotherapy. Stat News. \n                      https:\/\/www.statnews.com\/2017\/03\/08\/immunotherapy-cancer-breakthrough\/"},{"issue":"6280","key":"662_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockage [published online March 3, 2016]. Science. 2016;351(6280):1463\u20139. \n                      https:\/\/doi.org\/10.1126\/science.aaf1490\n                      \n                    .","journal-title":"Science"},{"key":"662_CR36","unstructured":"Begley S. The newest cancer therapies don\u2019t work on everyone. Now, doctors have a clue why. Stat News website. \n                      https:\/\/www.statnews.com\/2016\/03\/03\/cancer-immunotherapy-neoantigens\/\n                      \n                    . Published March 3, 3016. Accessed 21 Mar 2016"},{"key":"662_CR37","unstructured":"Garron E. Time to response to immunotherapy and the concept of pseudoprogression (video transcript). Global Resource for Advancing Cancer Education website. Published December 15, 2015. \n                      http:\/\/cancergrace.org\/lung\/2015\/12\/15\/gcvl_lu_immunotherapy_response_time_pseudoprogression_concept\/"},{"key":"662_CR38","unstructured":"Assessing immunotherapy response\u2014why irRC matters: clinical optimization. Institute for Clinical Immuno-Oncology website. \n                      http:\/\/accc-iclio.org\/resources\/assessing-immunotherapy-response-why-irrc-matters\/\n                      \n                    . Published June 25, 2015"},{"issue":"4","key":"662_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7497\/j.issn.2095-3941.2014.04.002","volume":"11","author":"T Kim","year":"2014","unstructured":"Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med. 2014;11(4):237\u201346. \n                      https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2014.04.002\n                      \n                    .","journal-title":"Cancer Biol Med"},{"issue":"1","key":"662_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semradonc.2014.07.004","volume":"25","author":"KA Pilones","year":"2015","unstructured":"Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015;25(1):28\u201333. \n                      https:\/\/doi.org\/10.1016\/j.semradonc.2014.07.004\n                      \n                    .","journal-title":"Semin Radiat Oncol"},{"issue":"15","key":"662_CR41","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman AM, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyper-progressors afterimmunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242\u201350. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3133\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"supple_6","key":"662_CR42","first-page":"1222P","volume":"27","author":"J Lahmar","year":"2016","unstructured":"Lahmar J, Mezquita L, Koscielny S, Facchinetti F, Bluthgen MV, Gazzah AA, et al. Immune checkpoint inhibitors (IC) induce paradoxical progress in a subset of non-small cell lung cancer (NSCLC). Ann Oncol. 2016;27(supple_6):1222P.","journal-title":"Ann Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0662-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T20:21:58Z","timestamp":1549484518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0662-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0662-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"7 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Debra L. Madden was a speaker at the American Journal of Managed Care (AJMC)\u2018s 5th Annual Patient-Centered Oncology Care meeting, where she gave a presentation from the perspective of a cancer research advocate and cancer survivor called \u201cImmunotherapy: The Promise, the Challenge, and the Patient.\u201d The AJMC covered all travel expenses and issued an honorarium as well. She has also served as a contributor to their website and blogged there with the same focus, but has received no compensation for her blog contributions. She also writes her own blog entitled \u201cMusings of a Cancer Research Advocate,\u201d from which she linked to her AJMC contributions, but has received no compensation for writing her blog.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"8"}}